[Edaily Reporter Kim Seung-kwon ] #SAMSUNG EPIS HOLDINGS announced on the 1st that it held an opening ceremony for its China R&D (Research and Development) center on the 30th of last month. This center marks SAMSUNG EPIS HOLDINGS’ first overseas R&D hub.
The building housing the China R&D Center (Photo: SAMSUNG EPIS HOLDINGS)
The company established the center as a field-specific organization to secure a technology platform centered on antibody-drug conjugates (ADCs) and strengthen its new drug development capabilities.
SAMSUNG EPIS HOLDINGS explained that Changping District in Beijing, where the center is located, is home to the Zhongguancun Life Sciences Park—a biotechnology industrial complex—and is adjacent to Peking University and Tsinghua University, making it an ideal location for leveraging research infrastructure and human resources.
Kim Kyung-ah, President of SAMSUNG EPIS HOLDINGS, said, “Going forward, we will work closely with the Chinese biotech ecosystem and strive to continuously expand new business initiatives, such as the discovery of innovative drug candidates.”
Consumers’ perspectives on brands are changing. There is a growing trend toward consuming not only a product’s taste or price but also the brand’s identity, atmosphere, and story. Particularly in the …
“Will you give me a name?”
A post titled “Newcomer Naming Service” featuring the official mascot, published on CJ Corp.’s official social media account. (Photo: Screenshot from CJ Corp.’s Instagram…
The Google app has surpassed Naver (NAVER(035420)) in monthly active users (MAU) in South Korea for three consecutive months. After the rankings flipped for the first time in July, Google maintained t…
